Terms, defined.

For purposes of the Investigational Drug Use Act: (1) Advanced illness means any progressive disease or medical or surgical condition that entails significant functional impairment, that is not considered by a treating physician to be reversible even with administration of federally approved and available treatments, and that, without life-sustaining procedures, would likely result in death within six months; (2) Eligible patient means a person who meets the requirements of section 71-9603; (3) Health care provider has the same meaning as in section 71-7907; (4) Investigational drug, biological product, or device means any drug, biological product, or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration; (5) Physician means any person who is licensed to practice medicine and surgery pursuant to the Medicine and Surgery Practice Act; and (6) Written, informed consent means a writing which conforms to section 71-9604.